ENIGMA Trademark

Trademark Overview


On Wednesday, December 2, 2020, a trademark application was filed for ENIGMA with the United States Patent and Trademark Office. The USPTO has given the ENIGMA trademark a serial number of 90354435. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Friday, May 3, 2024. This trademark is owned by CANADIAN NEUTRICEUTICAL HEALTH INC.. The ENIGMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, antivirals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Analgesic and muscle relaxant pharmaceutical preparations; Antimicrobial pre...
enigma

General Information


Serial Number90354435
Word MarkENIGMA
Filing DateWednesday, December 2, 2020
Status734 - FIFTH EXTENSION - GRANTED
Status DateFriday, May 3, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 28, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, antivirals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Analgesic and muscle relaxant pharmaceutical preparations; Antimicrobial preservatives for pharmaceuticals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, injectable contraceptives; Potassium preparations for pharmaceutical purposes; Pharmaceuticals, namely, psychotropics; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, antihelmintics; Pharmaceutical antitussive-cold preparations; Ocular pharmaceuticals; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, anticoagulants; Alcohol for pharmaceutical purposes; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Antibacterial pharmaceuticals; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Cardiovascular pharmaceuticals; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for treating halitosis; Pharmaceutical preparations for treating hypoglycemia; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for treating allergic rhinitis; Pharmaceutical preparations for treating asthma; Pharmaceutical products for the treatment of cancer

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 8, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCANADIAN NEUTRICEUTICAL HEALTH INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBolton, Ontario L7E5C1
CA

Party NameCANADIAN NEUTRICEUTICAL HEALTH INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBolton, Ontario L7E5C1
CA

Trademark Events


Event DateEvent Description
Saturday, December 5, 2020NEW APPLICATION ENTERED
Wednesday, May 19, 2021ASSIGNED TO EXAMINER
Monday, February 8, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 12, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 28, 2021NON-FINAL ACTION E-MAILED
Friday, May 28, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, May 28, 2021NON-FINAL ACTION WRITTEN
Wednesday, August 11, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 11, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 25, 2021EXAMINERS AMENDMENT E-MAILED
Wednesday, August 25, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, August 25, 2021EXAMINER'S AMENDMENT ENTERED
Wednesday, August 25, 2021EXAMINERS AMENDMENT -WRITTEN
Wednesday, August 25, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 8, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 28, 2021PUBLISHED FOR OPPOSITION
Tuesday, September 28, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 23, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, April 28, 2022SOU EXTENSION 1 FILED
Thursday, April 28, 2022SOU TEAS EXTENSION RECEIVED
Thursday, April 28, 2022SOU EXTENSION 1 GRANTED
Tuesday, May 2, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 2, 2023SOU EXTENSION 3 FILED
Saturday, April 30, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 10, 2022SOU TEAS EXTENSION RECEIVED
Thursday, November 10, 2022SOU EXTENSION 2 FILED
Thursday, November 10, 2022SOU EXTENSION 2 GRANTED
Saturday, November 12, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 2, 2023SOU EXTENSION 3 GRANTED
Thursday, May 4, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 3, 2024SOU EXTENSION 5 FILED
Friday, May 3, 2024SOU TEAS EXTENSION RECEIVED
Friday, May 3, 2024SOU EXTENSION 5 GRANTED
Saturday, May 4, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, November 25, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 23, 2023SOU TEAS EXTENSION RECEIVED
Thursday, November 23, 2023SOU EXTENSION 4 FILED
Thursday, November 23, 2023SOU EXTENSION 4 GRANTED